FUCA2 and lung carcinoma: Various GHs, including glucosidase II (90, 236), FUCA2 (86), NEU1 (83), and NEU3 (85), are overexpressed in lung cancer and have the potential to be utilized in the development of lung cancer-specific prodrugs.